Department of Veterans Affairs Office of Inspector General Training Act of 2023

Issues: 340B Program/Transparency; generics access; Pharmacy Benefit Managers; Prescription Drug Cost; Step Therapy Bills: S. 1114, Expanding Access to Low-Cost Generics Act To amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period. Sponsor: Sen. Smith, Tina [D-MN] S. 2305 - Biosimilar Red Tape Elimination Act To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Sponsor: Sen. Lee, Mike [R-UT] S. 148 - Stop STALLING Act A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. Sponsor: Sen. Amy Klobuchar (D-MN) S.1339 - Pharmacy Benefit Manager Reform Act To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage. Sponsor: Sen. Sanders, Bernard [I-VT] S. 775, Increasing Transparency in Generic Drug Applications To provide for increased transparency in generic drug applications. Sponsor: Sen. Hassan, Margaret Wood [D-NH] H.R.3839 - To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. Sponsor: Rep. Dunn, Neal P. [R-FL-2] S. 150 - Affordable Prescriptions for Patients Act of 2023 To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] H.R.9070 - Affordable Prescriptions for Patients Act of 2024 To amend title 35, United States Code, to prohibit product hopping, and for other purposes. Sponsor: Rep. Issa, Darrell [R-CA-48] S.1542, DRUG Act To improve services provided by pharmacy benefit managers. Sponsor: Sen. Marshall, Roger [R-KS] S. 142 - Preserve Access to Affordable Generics and Biosimilars Act To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S. 1067, Ensuring Timely Access to Generics Act To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] S.1041 - Affordable Prescriptions for Patients Act A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1040 - Drug Competition Enhancement Act A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1096 - Preserve Access to Affordable Generics and Biosimilars Act A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1095 - Stop STALLING Act A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. Sponsor: Sen. Klobuchar, Amy [D-MN]

Client expense: $210,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Issues: 340B Program/Transparency; generics access; Pharmacy Benefit Managers; Prescription Drug Cost; Step Therapy Bills: S. 1114, Expanding Access to Low-Cost Generics Act To amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period. Sponsor: Sen. Smith, Tina [D-MN] S. 2305 - Biosimilar Red Tape Elimination Act To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Sponsor: Sen. Lee, Mike [R-UT] S. 148 - Stop STALLING Act A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. Sponsor: Sen. Amy Klobuchar (D-MN) S.1339 - Pharmacy Benefit Manager Reform Act To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage. Sponsor: Sen. Sanders, Bernard [I-VT] S. 775, Increasing Transparency in Generic Drug Applications To provide for increased transparency in generic drug applications. Sponsor: Sen. Hassan, Margaret Wood [D-NH] H.R.3839 - To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. Sponsor: Rep. Dunn, Neal P. [R-FL-2] S. 150 - Affordable Prescriptions for Patients Act of 2023 To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] H.R.9070 - Affordable Prescriptions for Patients Act of 2024 To amend title 35, United States Code, to prohibit product hopping, and for other purposes. Sponsor: Rep. Issa, Darrell [R-CA-48] S.1542, DRUG Act To improve services provided by pharmacy benefit managers. Sponsor: Sen. Marshall, Roger [R-KS] S. 142 - Preserve Access to Affordable Generics and Biosimilars Act To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S. 1067, Ensuring Timely Access to Generics Act To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] S.1041 - Affordable Prescriptions for Patients Act A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1040 - Drug Competition Enhancement Act A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1096 - Preserve Access to Affordable Generics and Biosimilars Act A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1095 - Stop STALLING Act A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. Sponsor: Sen. Klobuchar, Amy [D-MN]

340B Program/Transparency; generics access; Pharmacy Benefit Managers; Prescription Drug Cost; Step Therapy S. 1114, Expanding Access to Low-Cost Generics Act To amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period. Sponsor: Sen. Smith, Tina [D-MN] S. 2305 - Biosimilar Red Tape Elimination Act To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Sponsor: Sen. Lee, Mike [R-UT] S. 148 - Stop STALLING Act A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. Sponsor: Sen. Amy Klobuchar (D-MN) S.1339 - Pharmacy Benefit Manager Reform Act To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage. Sponsor: Sen. Sanders, Bernard [I-VT] S. 775, Increasing Transparency in Generic Drug Applications To provide for increased transparency in generic drug applications. Sponsor: Sen. Hassan, Margaret Wood [D-NH] H.R.3839 - To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. Sponsor: Rep. Dunn, Neal P. [R-FL-2] S. 150 - Affordable Prescriptions for Patients Act of 2023 To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] H.R.9070 - Affordable Prescriptions for Patients Act of 2024 To amend title 35, United States Code, to prohibit product hopping, and for other purposes. Sponsor: Rep. Issa, Darrell [R-CA-48] S.1542, DRUG Act To improve services provided by pharmacy benefit managers. Sponsor: Sen. Marshall, Roger [R-KS] S. 142 - Preserve Access to Affordable Generics and Biosimilars Act To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S. 1067, Ensuring Timely Access to Generics Act To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] S.1041 - Affordable Prescriptions for Patients Act A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1040 - Drug Competition Enhancement Act A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1096 - Preserve Access to Affordable Generics and Biosimilars Act A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1095 - Stop STALLING Act A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. Sponsor: Sen. Klobuchar, Amy [D-MN]

Issues: 340B Program/Transparency; generics access; Pharmacy Benefit Managers; Prescription Drug Cost; Step Therapy Bills: S. 1114, Expanding Access to Low-Cost Generics Act To amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period. Sponsor: Sen. Smith, Tina [D-MN] S. 2305 - Biosimilar Red Tape Elimination Act To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Sponsor: Sen. Lee, Mike [R-UT] S. 148 - Stop STALLING Act A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. Sponsor: Sen. Amy Klobuchar (D-MN) S.1339 - Pharmacy Benefit Manager Reform Act To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage. Sponsor: Sen. Sanders, Bernard [I-VT] S. 775, Increasing Transparency in Generic Drug Applications To provide for increased transparency in generic drug applications. Sponsor: Sen. Hassan, Margaret Wood [D-NH] H.R.3839 - To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. Sponsor: Rep. Dunn, Neal P. [R-FL-2] S. 150 - Affordable Prescriptions for Patients Act of 2023 To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] H.R.9070 - Affordable Prescriptions for Patients Act of 2024 To amend title 35, United States Code, to prohibit product hopping, and for other purposes. Sponsor: Rep. Issa, Darrell [R-CA-48] S.1542, DRUG Act To improve services provided by pharmacy benefit managers. Sponsor: Sen. Marshall, Roger [R-KS] S. 142 - Preserve Access to Affordable Generics and Biosimilars Act To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S. 1067, Ensuring Timely Access to Generics Act To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] S.1041 - Affordable Prescriptions for Patients Act A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1040 - Drug Competition Enhancement Act A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1096 - Preserve Access to Affordable Generics and Biosimilars Act A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S.1095 - Stop STALLING Act A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. Sponsor: Sen. Klobuchar, Amy [D-MN]

340B Program/Transparency; generics access; Pharmacy Benefit Managers; Prescription Drug Cost; Step Therapy S. 1114, Expanding Access to Low-Cost Generics Act To amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period. Sponsor: Sen. Smith, Tina [D-MN] S. 2305 - Biosimilar Red Tape Elimination Act To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Sponsor: Sen. Lee, Mike [R-UT] S. 148 - Stop STALLING Act A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. Sponsor: Sen. Amy Klobuchar (D-MN) S.1339 - Pharmacy Benefit Manager Reform Act To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage. Sponsor: Sen. Sanders, Bernard [I-VT] S. 775, Increasing Transparency in Generic Drug Applications To provide for increased transparency in generic drug applications. Sponsor: Sen. Hassan, Margaret Wood [D-NH] H.R.3839 - To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. Sponsor: Rep. Dunn, Neal P. [R-FL-2] S. 150 - Affordable Prescriptions for Patients Act of 2023 To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] H.R.9070 - Affordable Prescriptions for Patients Act of 2024 To amend title 35, United States Code, to prohibit product hopping, and for other purposes. Sponsor: Rep. Issa, Darrell [R-CA-48] S.1542, DRUG Act To improve services provided by pharmacy benefit managers. Sponsor: Sen. Marshall, Roger [R-KS] S. 142 - Preserve Access to Affordable Generics and Biosimilars Act To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S. 1067, Ensuring Timely Access to Generics Act To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] S.1041 - Affordable Prescriptions for Patients Act A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1040 - Drug Competition Enhancement Act A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1096 - Preserve Access to Affordable Generics and Biosimilars Act A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN]

Department of Veterans Affairs appropriations and its delivery of benefits and services to veterans, their dependents and survivors: H.Res. 535, H.Res. 612, H.Res. 674, H.Res. 720, H.Res. 740 H.J. Res. 33, HR 1001, HR 1003, HR 104, HR 1078, HR 1083, HR 1089, HR 1097, HR 1139, HR 1144, HR 1166, HR 1169, HR 1179, HR 1182, HR 1188, HR 1191, HR 1226, HR 1266, HR 1277, HR 1278, HR 1282, HR 1311, HR 1315, HR 1329, HR 1378, HR 1402, HR 1529, HR 1530, HR 1554, HR 1606, HR 1609, HR 1616, HR 1639, HR 1655, HR 1659, HR 1669, HR 1708, HR 1753, HR 1767, HR 1774, HR 1786, HR 1799, HR 1815, HR 1822, HR 1948, HR 1950, HR 196, HR 226, HR 228, HR 232, HR 234, HR 236, HR 2398, HR 2410, HR 2413, HR 2414, HR 2431, HR 2441, HR 2469, HR 2472, HR 2499, HR 251, HR 2518, HR 2525, HR 2526, HR 2543, HR 2733, HR 2768, HR 2809, HR 2828, HR 2830, HR 2846, HR 2896, HR 2932, HR 2971, HR 3023, HR 303, HR 3040, HR 3084, HR 3110, HR 3128, HR 3157, HR 3186, HR 3192, HR 3214, HR 3225, HR 3303, HR 3326, HR 333, HR 3363, HR 3368, HR 3450, HR 3489, HR 3499, HR 3504, HR 3511, HR 3581, HR 3584, HR 3600, HR 3601, HR 3644, HR 3648, HR 3649, HR 3651, HR 3676, HR 3677, HR 3698, HR 3718, HR 3720, HR 3722, HR 3751, HR 3790, HR 3811, HR 3848, HR 3870, HR 3895, HR 394, HR 395, HR 4047, HR 41, HR 411, HR 4150, HR 4157, HR 4249, HR 4262, R 4325, HR 4566, HR 4569, HR 4634, HR 4670, HR 4886, HR 4906, HR 491, HR 492, HR 4921, HR 4944, HR 5002, HR 5014, HR 5147, HR 5153, HR 516, HR 5197, HR 522, HR 523, HR 5247, HR 5259, HR 5287, HR 5365, HR 5367, HR 5377, HR 5416, HR 542, HR 5425, HR 543, HR 544, HR 5470, HR 5492, HR 5530, HR 5559, HR 5610, HR 5633, HR 5682, HR 5697, HR 5702, HR 5794, HR 5860, HR 5870, HR 5904, HR 592, HR 602, HR 608, HR 626, HR 645, HR 693, HR 716, HR 728, HR 733, HR 746, HR 754, HR 768, HR 808, HR 815, HR 854, HR 885, HR 894, HR 903, HR 984, S 10, S 1028, S 1037, S 1040, S 106, S 1090, S 1096, S 1100, S 1119, S 1125, S 1172, S 1266, S 1309, S 1314, S 132, S 1330, S 1360, S 141, S 1436, S 1469, S 1515, S 1590, S 1612, S 1635, S 1678, S 1792, S 1828, S 185, S 1951, S 1954, S 1975, S 1994, S 2014, S 2026, S 216, S 2294, S 2315, S 2386, S 24, S 2422, S 2431, S 2465, S 2503, S 2513, S 2516, S 263, S 2679, S 2718, S 2720, S 2745, S 2757, S 2778, S 2795, S 280, S 2801, S 2803, S 2854, S 2863, S 2873, S 291, S 296, S 2975, S 30, S 302, S 326, S 330, S 344, S 350, S 38, S 414, S 42, S 449, S 495, S 498, S 528, S 531, S 547, S 592, S 596, S 609, S 622, S 633, S 656, S 665, S 680, S 725, S 740, S 748, S 774, S 777, S 853, S 897, S 928, S.J. Res. 17, S.Res. 208, S.Res. 264, S.Res. 335, S.Res. 348, S. Res. 365, S. Res. 405

Department of Veterans Affairs appropriations and its delivery of benefits and services to veterans, their dependents and survivors: H.Res. 535, H.J. Res. 33, HR 1001, HR 1003, HR 104, HR 1078, HR 1083, HR 1089, HR 1097, HR 1139, HR 1144, HR 1166, HR 1169, HR 1179, HR 1182, HR 1188, HR 1191, HR 1226, HR 1266, HR 1277, HR 1278, HR 1282, HR 1311, HR 1315, HR 1329, HR 1378, HR 1402, HR 1529, HR 1530, HR 1554, HR 1606, HR 1609, HR 1616, HR 1639, HR 1655, HR 1659, HR 1669, HR 1708, HR 1753, HR 1767, HR 1774, HR 1786, HR 1799, HR 1815, HR 1822, HR 1948, HR 1950, HR 196, HR 226, HR 228, HR 232, HR 234, HR 236, HR 2398, HR 2410, HR 2413, HR 2414, HR 2431, HR 2441, HR 2469, HR 2472, HR 2499, HR 251, HR 2518, HR 2525, HR 2526, HR 2543, HR 2733, HR 2768, HR 2809, HR 2828, HR 2830, HR 2846, HR 2896, HR 2932, HR 2971, HR 3023, HR 303, HR 3040, HR 3084, HR 3110, HR 3128, HR 3157, HR 3186, HR 3192, HR 3214, HR 3225, HR 3303, HR 3326, HR 333, HR 3363, HR 3368, HR 3450, HR 3489, HR 3499, HR 3504, HR 3511, HR 3581, HR 3584, HR 3600, HR 3601, HR 3644, HR 3648, HR 3649, HR 3651, HR 3676, HR 3677, HR 3698, HR 3718, HR 3720, HR 3722, HR 3751, HR 3790, HR 3811, HR 3848, HR 3870, HR 3895, HR 394, HR 395, HR 4047, HR 41, HR 411, HR 4150, HR 4157, HR 4249, HR 4262, HR 4325, HR 4566, HR 491, HR 492, HR 516, HR 522, HR 523, HR 542, HR 543, HR 544, HR 592, HR 602, HR 608, HR 626, HR 645, HR 693, HR 716, HR 728, HR 733, HR 746, HR 754, HR 768, HR 808, HR 815, HR 854, HR 885, HR 894, HR 903, HR 984, S 10, S 1028, S 1037, S 1040, S 106, S 1090, S 1096, S 1100, S 1119, S 1125, S 1172, S 1266, S 1309, S 1314, S 132, S 1330, S 1360, S 141, S 1436, S 1469, S 1515, S 1590, S 1612, S 1635, S 1678, S 1792, S 1828, S 185, S 1951, S 1954, S 1975, S 1994, S 2014, S 2026, S 216, S 2294, S 24, S 263, S 280, S 291, S 296, S 30, S 302, S 326, S 330, S 344, S 350, S 38, S 414, S 42, S 449, S 495, S 498, S 528, S 531, S 547, S 592, S 596, S 609, S 622, S 633, S 656, S 665, S 680, S 725, S 740, S 748, S 774, S 777, S 853, S 897, S 928, S.J. Res. 17, S.Res. 208, S.Res. 264

Department of Veterans Affairs appropriations and its delivery of benefits and services to veterans, their dependents and survivors: H.J. Res. 33, HR 1001, HR 1003, HR 104, HR 1078, HR 1083, HR 1089, HR 1097, HR 1139, HR 1144, HR 1166, HR 1169, HR 1179, HR 1182, HR 1188, HR 1191, HR 1226, HR 1266, HR 1277, HR 1278, HR 1282, HR 1311, HR 1329, HR 1378, HR 1402, HR 1529, HR 1530, HR 1554, HR 1606, HR 1609, HR 1616, HR 1639, HR 1655, HR 1659, HR 1669, HR 1708, HR 1753, HR 1767, HR 1774, HR 1786, HR 1799, HR 1815, HR 1822, HR 1948, HR 1950, HR 196, HR 226, HR 228, HR 232, HR 234, HR 236, HR 2398, HR 2410, HR 2413, HR 2414, HR 2431, HR 2441, HR 2469, HR 2472, HR 2499, HR 251, HR 2518, HR 2525, HR 2526, HR 303, HR 333, HR 394, HR 395, HR 41, HR 411, HR 491, HR 492, HR 516, HR 522, HR 523, HR 542, HR 543, HR 544, HR 592, HR 602, HR 608, HR 626, HR 645, HR 693, HR 716, HR 728, HR 733, HR 746, HR 754, HR 768, HR 808, HR 815, HR 854, HR 885, HR 894, HR 903, HR 984, S 10, S 1028, S 1037, S 1040, S 106, S 1090, S 1096, S 1100, S 1119, S 1125, S 132, S 141, S 185, S 216, S 24, S 263, S 280, S 296, S 30, S 302, S 326, S 330, S 344, S 38, S 414, S 42, S 449, S 495, S 528, S 531, S 547, S 592, S 596, S 609, S 622, S 633, S 656, S 665, S 680, S 725, S 740, S 748, S 777, S 853, S 897, S 928, S.J. Res. 17

Client expense: $183,150 · Firm income: Not reported